drugset / Trial / NCT05583071
Methotrexate, Tafasitamab, Lenalidomide and Rituximab in Patients With PCNSL
NaSingle-groupOpen-labelTreatment
Summary
Pilot-trial of Methotrexate, Tafasitamab (Minjuvi®), Lenalidomide (Revlimid®) and Rituximab in patients ineligible for HCT-ASCT with Primary Central Nervous System Lymphoma (PCNSL)
Timeline
- Start
- 2024-08-23
- Primary completion
- 2027-02
- Completion
- 2027-04
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Lenalidomide | Other / unclassified | 25 mg | Oral |
| Subject | Methotrexate | Small molecule | 3.5 g | — |
| Subject | Rituximab | Monoclonal antibody | 375 mg/m2 | — |
| Subject | Tafasitamab | Monoclonal antibody | 12 mg/kg | — |